Vineti, Inc., a San Francisco, CA-based digital platform of record for personalized therapeutics, closed a $33m extension to its Series C financing.
The Series C extension is led by Cardinal Health, with participation from Marc Benioff and existing Vineti investors, including Canaan Partners, Threshold Ventures (formerly DFJ), Section 32, Casdin Capital, Novartis Pharma AG, McKesson Ventures, and LifeForce Capital, along with other undisclosed entities. Eli Casdin, Chief Investment Officer and Founder of Casdin Capital, will join Vineti’s Board of Directors.
The new financing will support further expansion of the company’s Personalized Therapy Management (PTM) ® platform for personalized and high-value advanced therapies.
Co-founded by GE and the Mayo Clinic and led by Amy DuRoss, CEO, Vineti provides a commercial, configurable cloud-based platform expanding patient access to life-saving cell and gene therapies. Now a fully independent company, Vineti offers a digital platform of record to integrate logistics, manufacturing, and clinical data for personalized therapies.
The platform supports the full continuum of patient-specific therapies, including cancer vaccines and autologous and allogeneic cell therapies. The platform can also be harnessed for drug products requiring companion diagnostics or REMS programs. Vineti is currently serving patients, healthcare providers, and researchers in hundreds of leading medical centers and manufacturing centers world-wide, on behalf of a growing number of biopharmaceutical partners.
The company also has offices in Bethesda, Maryland and Yerevan, Armenia.